Pneumocystis jirovecii en pacientes inmunocomprometidos con enfermedades reumáticas

Falagas, 2007, Infection-related morbidity and mortality in patients with connective tissue diseases: a systematic review, Clin Rheumatol., 26, 663, 10.1007/s10067-006-0441-9 Faria, 2015, Chapter 15 - Opportunistic Infections and Autoimmune Diseases, 251 Garred, 2001, Association of mannose-binding lectin gene variation with disease severity and infections in a population-based cohort of systemic lupus erythematosus patients, Genes Immun., 2, 442, 10.1038/sj.gene.6363804 Doran, 2002, Frequency of infection in patients with rheumatoid arthritis compared with controls: a population-based study, Arthritis Rheum., 46, 2287, 10.1002/art.10524 Catherinot, 2010, Pneumocystis jirovecii Pneumonia, Infect Dis Clin N Am., 24, 107, 10.1016/j.idc.2009.10.010 Hof, 2012, Pneumocystis jirovecii: A peculiar fungus posing particular problems for therapy and prophylaxis, Mycoses., 55, 1, 10.1111/j.1439-0507.2011.02159.x Huang, 2018, Echinocandins for Pneumocystis jirovecii pneumonia in non-HIV patients: A case report, Exp Ther Med., 16, 3227 Thomas, 2004, Pneumocystis Pneumonia, N Engl J Med., 350, 2487, 10.1056/NEJMra032588 Mofenson, 2009, MMWR Recomm Rep., 58, 1 Centers for Disease Control and Prevention. Fungal Diseases: Pneumocystis pneumonia 2017 Disponible en: https://www.cdc.gov/fungal/diseases/pneumocystis-pneumonia/index.html Vogel, 2012, HRCT-features of Pneumocystis jirovecii pneumonia and their evolution before and after treatment in non-HIV immunocompromised patients, Eur J Radiol., 81, 1315, 10.1016/j.ejrad.2011.02.052 Cooley, 2014, Consensus guidelines for diagnosis, prophylaxis and management of Pneumocystis jirovecii pneumonia in patients with haematological and solid malignancies, 2014, Intern Med J., 44, 1350, 10.1111/imj.12599 Chen, 2015, Pneumocystis Pneumonia in Patients with Autoimmune Diseases: A Retrospective Study Focused on Clinical Characteristics and Prognostic Factors Related to Death, PLoS One., 10, e0139144, 10.1371/journal.pone.0139144 Mansharamani, 2000, Management and outcome patterns for adult Pneumocystis carinii pneumonia, 1985 to 1995: comparison of HIV-associated cases to other immunocompromised states, Chest., 118, 704, 10.1378/chest.118.3.704 Ward, 1999, Pneumocystis carinii pneumonia in patients with connective tissue diseases: the role of hospital experience in diagnosis and mortality, Arthritis Rheum., 42, 780, 10.1002/1529-0131(199904)42:4<780::AID-ANR23>3.0.CO;2-M Walzer, 1973, Pneumocystis carinii pneumonia and primary immune deficiency diseases of infancy and childhood, J Pediatr., 82, 416, 10.1016/S0022-3476(73)80114-3 Yale, 1996, Pneumocystis carinii pneumonia in patients without acquired immunodeficiency syndrome: associated illnesses and prior corticosteroid therapy, May Clin Proc., 71, 5, 10.4065/71.1.5 U.S. Department of Health and Human Services, AIDSinfo. Guidelines for the Prevention and Treatment of Opportunistic Infections in Adults and Adolescents with HIV: Pneumocystis Pneumonia 2019 Disponible en: https://aidsinfo.nih.gov/guidelines/html/4/adult-and-adolescent-opportunistic-infection/321/pneumocystis-pneumonia Fillatre, 2014, Incidence of Pneumocystis jirovecii pneumonia among groups at risk in HIV-negative patients, Am J Med., 127, e11, 10.1016/j.amjmed.2014.07.010 Stamp, 2010, Is there a role for consensus guidelines for P. jiroveci pneumonia prophylaxis in immunosuppressed patients with rheumatic diseases?, J Rheumatol., 37, 686, 10.3899/jrheum.091426 Wolfe, 2017, Pneumocystis Pneumonia and the Rheumatologist: Which Patients Are At Risk and How Can PCP Be Prevented?, Curr Rheumatol Rep., 19, 35, 10.1007/s11926-017-0664-6 Cettomai, 2010, A survey of rheumatologists’ practice for prescribing pneumocystis prophylaxis, J Rheumatol., 37, 792, 10.3899/jrheum.090843 Gupta, 2008, Prophylactic antibiotic usage for Pneumocystis jirovecii pneumonia in patients with systemic lupus erythematosus on cyclophosphamide: a survey of US rheumatologists and the review of literature, J Clin Rheumatol., 14, 267, 10.1097/RHU.0b013e31817a7e30 Park, 2018, Prophylactic effect of trimethoprim-sulfamethoxazole for pneumocystis pneumonia in patients with rheumatic diseases exposed to prolonged high-dose glucocorticoids, Ann Rheum Dis., 77, 644, 10.1136/annrheumdis-2017-211796 Green, 2007, Prophylaxis of Pneumocystis pneumonia in immunocompromised non-HIV-infected patients: systematic review and meta-analysis of randomized controlled trials, Mayo Clin Proc., 82, 1052, 10.4065/82.9.1052 Tejera Segura, 2019, Can we validate a clinical score to predict the risk of severe infection in patients with systemic lupus erythematosus? A longitudinal retrospective study in a British Cohort, BMJ Open., 9, e028697, 10.1136/bmjopen-2018-028697 Li, 2006, Pneumocystis carinii pneumonia in patients with connective tissue disease, J Clin Rheumatol., 12, 114, 10.1097/01.rhu.0000221794.24431.36 Godeau, 1994, Pneumocystis carinii pneumonia in the course of connective tissue disease: report of 34 cases, J Rheumatol., 21, 246 Godeau, 1995, Factors associated with Pneumocystis carinii pneumonia in Wegener's granulomatosis, Ann Rheum Dis., 54, 991, 10.1136/ard.54.12.991 Yates, 2016, EULAR/ERA-EDTA recommendations for the management of ANCA-associated vasculitis, Ann Rheum Dis., 75, 1583, 10.1136/annrheumdis-2016-209133 Kronbichler, 2015, Frequency, risk factors and prophylaxis of infection in ANCA-associated vasculitis, Eur J Clin Invest., 45, 346, 10.1111/eci.12410 Kermani, 2011, Pneumocystis jirovecii pneumonia in giant cell arteritis: A case series, Arthritis Care Res (Hoboken)., 63, 761, 10.1002/acr.20435 Mukhtyar, 2009, EULAR recommendations for the management of large vessel vasculitis, Ann Rheum Dis., 68, 318, 10.1136/ard.2008.088351 Hellmich, 2020, 2018 Update of the EULAR recommendations for the management of large vessel vasculitis, Ann Rheum Dis., 79, 19, 10.1136/annrheumdis-2019-215672 Dasgupta, 2010, BSR and BHPR guidelines for the management of giant cell arteritis, Rheumatology., 49, 1594, 10.1093/rheumatology/keq039a Lertnawapan, 2009, Risk factors of Pneumocystis jerovecii pneumonia in patients with systemic lupus erythematosus, Rheumatol Int., 29, 491, 10.1007/s00296-008-0721-6 Suyama, 2019, Can we prescribe TMP/SMX prophylaxis without any concerns equally for all patients with rheumatic disease?, Ann Rheum Dis., 78, e17, 10.1136/annrheumdis-2018-213027 Suyama, 2016, Safety and efficacy of upfront graded administration of trimethoprim–sulfamethoxazole in systemic lupus erythematosus: A retrospective cohort study, Modern Rheumatology., 26, 557, 10.3109/14397595.2015.1112467 Barber, 2011, Infections in the lupus patient: perspectives on prevention, Curr Opin Rheumatol., 23, 358, 10.1097/BOR.0b013e3283476cd8 Fanouriakis, 2019, 2019 Update of the EULAR recommendations for the management of systemic lupus erythematosus, Ann Rheum Dis., 78, 736, 10.1136/annrheumdis-2019-215089 Marie, 2011, Infectious complications in polymyositis and dermatomyositis: a series of 279 patients, Semin Arthritis Rheum., 41, 48, 10.1016/j.semarthrit.2010.08.003 Mori, 2012, Pneumocystis jirovecii infection: an emerging threat to patients with rheumatoid arthritis, Rheumatology (Oxford)., 51, 2120, 10.1093/rheumatology/kes244 Mori, 2015, Pneumocystis jirovecii pneumonia in rheumatoid arthritis patients: risks and prophylaxis recommendations, Clin Med Insights Circ Respir Pulm Med., 9, 29 Walzer, 1984, Lymphocyte changes during chronic administration of and withdrawal from corticosteroids: relation to Pneumocystis carinii pneumonia, J Immunol., 133, 2502, 10.4049/jimmunol.133.5.2502 Vananuvat, 2011, Primary prophylaxis for Pneumocystis jirovecii pneumonia in patients with connective tissue diseases, Semin Arthritis Rheum., 41, 497, 10.1016/j.semarthrit.2011.05.004 Sepkowitz, 1996, Pneumocystis carinii pneumonia without acquired immunodeficiency syndrome: who should receive prophylaxis?, Mayo Clin Proc., 71, 102, 10.4065/71.1.102 Duru, 2013, EULAR evidence-based and consensus-based recommendations on the management of medium to high-dose glucocorticoid therapy in rheumatic diseases, Ann Rheum Dis., 72, 1905, 10.1136/annrheumdis-2013-203249 Hoes, 2007, EULAR evidence-based recommendations on the management of systemic glucocorticoid therapy in rheumatic diseases, Ann Rheum Dis., 66, 1560, 10.1136/ard.2007.072157 van der Goes, 2010, Monitoring adverse events of low-dose glucocorticoid therapy: EULAR recommendations for clinical trials and daily practice, Ann Rheum Dis., 69, 1913, 10.1136/ard.2009.124958 Tadros, 2017, Pneumocystis jirovecii pneumonia in systemic autoimmune rheumatic disease: A case-control study, Semin Arthritis Rheum., 46, 804, 10.1016/j.semarthrit.2016.09.009 Rutherford, 2018, Opportunistic infections in rheumatoid arthritis patients exposed to biologic therapy: results from the British Society for Rheumatology Biologics Register for Rheumatoid Arthritis, Rheumatology (Oxford)., 57, 997, 10.1093/rheumatology/key023 Bryant, 2017, Opportunistic Infections in Biological Therapy Risk and Prevention, Rheum Dis Clin North Am., 43, 27, 10.1016/j.rdc.2016.09.005 Ogawa, 2005, Prediction of and prophylaxis against Pneumocystis pneumonia in patients with connective tissue diseases undergoing medium- or high-dose corticosteroid therapy, Mod Rheumatol., 15, 91, 10.3109/PL00021707 Mansharamani, 2000, Peripheral blood CD4 + T-lymphocyte counts during Pneumocystis carinii pneumonia in immunocompromised patients without HIV Infection, Chest., 118, 712, 10.1378/chest.118.3.712 Sowden, 2004, Autoimmune inflammatory disorders, systemic corticosteroids and pneumocystis pneumonia: a strategy for prevention, BMC Infect Dis., 4, 42, 10.1186/1471-2334-4-42 Porges AJ, Beattie SL, Ritchlin C, Kimberly RP, Christian CL. Patients with systemic lupus erythematosus at risk for Pneumocystis carinii pneumonia. J Rheumatol 1992;19(8):1191-4. Avino, 2016, Pneumocystis jirovecii pneumonia in the Non–HIV-Infected Population, Ann Pharmacother., 50, 673, 10.1177/1060028016650107 Stern, 2014, Prophylaxis for Pneumocystis pneumonia (PCP) in non-HIV immunocompromised patients, Cochrane Database of Systematic Reviews., 10.1002/14651858.CD005590.pub3 Bourré-Tessier, 2010, Methotrexate drug interactions in the treatment of rheumatoid arthritis: a systematic review, J Rheumatol., 37, 1416, 10.3899/jrheum.090153 Smilack, 1999, Trimethoprim-sulfamethoxazole, Mayo Clin Proc., 74, 730, 10.4065/74.7.730 Ho, 2011, Considerations when prescribing trimethoprim–sulfamethoxazole, CMAJ., 183, 1851, 10.1503/cmaj.111152 Mecoli, 2017, Pneumocystis jirovecii pneumonia in rheumatic disease: a 20-year single-centre experience, Clin Exp Rheumatol., 35, 671 Chew, 2015, Pneumocystis jirovecii pneumonia in patients with autoimmune disease on high-dose glucocorticoid, J Clin Rheumatol., 21, 72, 10.1097/RHU.0000000000000215 Demoruelle, 2013, Recent-onset systemic lupus erythematosus complicated by acute respiratory failure, Arthritis Care Res (Hoboken)., 65, 314, 10.1002/acr.21857 Herrou, 2020, Predictive factors of pneumocystis pneumonia in patients with rheumatic diseases exposed to prolonged high-dose glucocorticoids, Ann Rheum Dis., 79, e23, 10.1136/annrheumdis-2018-214718